Urology News and Research

Latest Urology News and Research

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that a compound identified by the Company as an antagonist of GPR87, an orphan GPCR recently unlocked for drug development by Omeros and linked to squamous cell carcinoma, potentiates the tumor-killing activity of doxorubicin (Adriamycin), a widely used chemotherapeutic agent.

10 Nov 2010

Long-term use of statins unlikely to substantially increase overall cancer risk: Study

Researchers have further established that long-term use of statins is unlikely to substantially increase or decrease overall cancer risk, according to study results presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held Nov. 7-10, 2010, in Philadelphia.

10 Nov 2010

Research may help develop new therapies for aggressive prostate cancer

A monoclonal antibody targeting a well known cell surface protein inhibited prostate cancer growth and metastasis in an aggressive form of the disease that did not respond to hormone therapy, according to a study by researchers with the UCLA Department of Urology and UCLA's Jonsson Comprehensive Cancer Center.

9 Nov 2010

New approach to treat castration resistant prostate cancer

9 Nov 2010

Watson third quarter net revenue increases 33% to $882.4 million

Watson Pharmaceuticals, Inc. today reported net revenue grew 33 percent for the third quarter ended September 30, 2010 to $882.4 million, compared to $662.1 million in the third quarter 2009. On an adjusted cash basis, net income increased 18 percent to $105.9 million or $0.85 per share, compared to $90.0 million or $0.78 per share in the third quarter 2009.

4 Nov 2010

Nymox awarded federal grant for NX-1207 Phase III BPH clinical trial program

Nymox Pharmaceutical Corporation announced today that it has been awarded a grant of $244,479.25 from the U.S Government under the Qualifying Therapeutic Discovery Project for its ongoing Phase III clinical trial program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH). The grant was the maximum allowable for an individual development program.

4 Nov 2010

Medicare reimbursement cuts lead to decline in unnecessary or inappropriate care

When Medicare policy changes led to reductions in reimbursement for hormonal treatment of prostate cancer, there was a sharp decline in its use among patients not likely to benefit from the treatment. But among patients for whom the therapy is clearly beneficial, doctors continued to prescribe it at the same rate, according to a new study.

4 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

AHRQ study finds prostate cancer mortality rate declines by 45%

According to the U.S. Agency for Healthcare Research and Quality (AHRQ), compared to men in 1999, American men in 2006 that were fighting prostate cancer were 45% less likely to die from the disease.

3 Nov 2010

Watson enters exclusive agreement with OMJPI to market authorized generic Concerta

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has entered into an exclusive agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), to market the authorized generic version of Concerta® (methylphenidate hydrochloride extended-release tablets). Watson will launch its authorized generic of Concerta on May 1, 2011. Concerta is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).

2 Nov 2010

New targeted therapy shows positive results in patients with lung cancer

A UC Irvine oncologist's work with a targeted therapy is showing great promise in patients with a deadly form of lung cancer. The results were published Thursday in the New England Journal of Medicine.

2 Nov 2010

Calypso Medical to showcase FDA cleared Dynamic Edge Gating Technology at 52nd ASTRO

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced it will showcase Dynamic Edge™ Gating Technology, recently cleared by the U.S. Food and Drug Administration, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO), now underway at the San Diego Convention Center.

1 Nov 2010

Allergan third quarter diluted loss per share increases to $2.21

Allergan, Inc. today announced operating results for the quarter ended September 30, 2010. Allergan also announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on December 1, 2010 to stockholders of record on November 10, 2010.

1 Nov 2010

Endo third quarter total revenues increase 23% to $444.1 million

Endo Pharmaceuticals today reported financial results for the third quarter 2010.

1 Nov 2010

Saving soldier's life takes precedence over treating traumatic urologic injury on battlefield

Saving a soldier's life takes precedence over treating traumatic urologic injuries on the battlefield, a Medical College of Georgia researcher says.

30 Oct 2010

Physicians suggest patients who receive MoM hip replacement to pay attention on post-operative pain

Total hip arthroplasty (THA) is one of the most successful surgeries of the past several decades. This procedure has relieved pain and restored movement to hundreds of thousands of people. The decision to have hip replacement surgery should be only made after discussion between the patient and his or her orthopaedic surgeon.

30 Oct 2010

Karmanos, WSU SOM present long-term results of fast neutron radiotherapy in localized prostate cancer

Scientists from the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine (WSU SOM) in Detroit will present the world's largest study that shows the long-term results of fast neutron radiotherapy (FNRT) in the treatment of localized prostate cancer. The findings will be formally announced Tuesday, Nov. 2, at the American Society of Therapeutic Radiology and Oncology (ASTRO) Annual Meeting

30 Oct 2010

Coloplast announces acquisition of Mpathy Medical

Coloplast announced today that it has acquired Mpathy Medical, a fast growing company in women's health, for a total cash consideration of USD 30m equal to DKK162m, potentially increasing to a total of USD 35m equal to DKK 189m on a cash and debt free basis. The acquisition expands the Coloplast female health portfolio of innovative product technologies and surgical solutions for female stress urinary incontinence and pelvic organ prolapse.

29 Oct 2010

NeoGenomics third quarter revenue grows 19% to $8.7 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the third quarter 2010.

28 Oct 2010

NICE issues PTNS guidance for overactive bladder

Uroplasty, Inc. announced today that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) issued a guidance document titled "Percutaneous Posterior Tibial Nerve Stimulation for Overactive Bladder Syndrome," reinforcing the safety and effectiveness of PTNS for overactive bladder.

28 Oct 2010

Urology News and Research

Latest Urology News and Research

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Long-term use of statins unlikely to substantially increase overall cancer risk: Study

Research may help develop new therapies for aggressive prostate cancer

New approach to treat castration resistant prostate cancer

Watson third quarter net revenue increases 33% to $882.4 million

Nymox awarded federal grant for NX-1207 Phase III BPH clinical trial program

Medicare reimbursement cuts lead to decline in unnecessary or inappropriate care

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

AHRQ study finds prostate cancer mortality rate declines by 45%

Watson enters exclusive agreement with OMJPI to market authorized generic Concerta

New targeted therapy shows positive results in patients with lung cancer

Calypso Medical to showcase FDA cleared Dynamic Edge Gating Technology at 52nd ASTRO

Allergan third quarter diluted loss per share increases to $2.21

Endo third quarter total revenues increase 23% to $444.1 million

Saving soldier's life takes precedence over treating traumatic urologic injury on battlefield

Physicians suggest patients who receive MoM hip replacement to pay attention on post-operative pain

Karmanos, WSU SOM present long-term results of fast neutron radiotherapy in localized prostate cancer

Coloplast announces acquisition of Mpathy Medical

NeoGenomics third quarter revenue grows 19% to $8.7 million

NICE issues PTNS guidance for overactive bladder

Forensics and toxicology - Industry Focus eBook eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Urology News and Research

Latest Urology News and Research

Forensics and toxicology - Industry Focus eBook eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in